It’s not the size of the trial that’s most important it’s the size of the shift. In the case of CD33 it’s proving the concept against a wide range of cancers. And further optimisation of the dose plus identifying the best application which includes which patients are most likely to get a benefit over and above other treatments available.
LC has been involved in over 200 trials . At least give her the credit she has earned . Rather than implying she has steered IMU in the wrong direction.
When was the last time you were in a high level meeting with the Oncology experts at the FDA or a Big Pharma company?
Media Thread, page-13999
-
- There are more pages in this discussion • 666 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |